NGSX News 0.0069 Neurogesx (NGSX)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Neurogesx (NGSX) 0.0069 $NGSX

OTC Signal Daily Stock Watch - NeurogesX, Inc., (OTC:NGSX)
WorldStockWire - Wed Sep 04, 6:15PM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com

Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2012
M2 - Fri Aug 02, 6:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/93dth7/peripheral) has announced the addition of the "Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for peripheral neuropathy (sensory neuropathy), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for peripheral neuropathy (sensory neuropathy). The information is built using data and information sourced from proprietary databases, company/university websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for peripheral neuropathy (sensory neuropathy). - A review of the peripheral neuropathy (sensory neuropathy) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the peripheral neuropathy (sensory neuropathy) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Report Coverage Peripheral Neuropathy (Sensory Neuropathy) Overview Therapeutics Development An Overview of Pipeline Products for Peripheral Neuropathy (Sensory Neuropathy) Companies Involved in Peripheral Neuropathy (Sensory Neuropathy) Therapeutics Development Drug Profiles Featured News & Press Releases Appendix Companies Mentioned - Allon Therapeutics Inc - Neuren Pharmaceuticals Limited - NeurogesX, Inc - NsGene A/S For more information visit http://www.researchandmarkets.com/research/93dth7/peripheral

Postherpetic Neuralgia - Pipeline Review, H2 2012
M2 - Thu Aug 01, 5:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f66v5t/postherpetic) has announced the addition of the "Postherpetic Neuralgia - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. It also provides information on the therapeutic development for Postherpetic Neuralgia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Postherpetic Neuralgia. The data is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Postherpetic Neuralgia. - A review of the Postherpetic Neuralgia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Postherpetic Neuralgia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Report Coverage Postherpetic Neuralgia Overview Therapeutics Development An Overview of Pipeline Products for Postherpetic Neuralgia Companies Involved in Postherpetic Neuralgia Therapeutics Development Drug Profiles with Product Descriptions and Mechanisms of Action Featured News & Press Releases Appendix Companies Mentioned: - Allergan, Inc - Amgen Inc - Arcion Therapeutics - Bial - Portela & Ca, S.A - Bristol-Myers Squibb Company - Celtic Pharmaceutical Holdings L.P - DURECT Corporation - Daewoong Pharmaceutical Co - EpiCept Corporation - Kyowa Hakko Kirin Co - NeurogesX, Inc - SantoSolve AS - Spinifex Pharmaceuticals Pty Limited - TheraQuest Biosciences, LLC - Valeant Pharmaceuticals International - Winston Pharmaceuticals - Xenon Pharmaceuticals Inc For more information visit http://www.researchandmarkets.com/research/f6...stherpetic

Peripheral Neuropathic Pain - Pipeline Review, H1 2013
M2 - Wed Jul 17, 10:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/94lzdl/peripheral) has announced the addition of the "Peripheral Neuropathic Pain - Pipeline Review, H1 2013" report to their offering. 'Peripheral Neuropathic Pain - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Peripheral Neuropathic Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Peripheral Neuropathic Pain. Scope - A snapshot of the global therapeutic scenario for Peripheral Neuropathic Pain. - A review of the Peripheral Neuropathic Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature o

Acorda Expands Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 11, 5:20PM CDT
The company acquired Qutenza and NP-1998 from NeurogesX, Inc.

Acorda Therapeutics Inc acquires two neuropathic pain assets for approximately USD8m from NeurogesX Inc
M2 - Wed Jul 10, 4:59AM CDT
Biotechnology company Acorda Therapeutics Inc (Nasdaq:ACOR) revealed on Tuesday that it has completed its acquisition of two neuropathic pain management assets, Qutenza and NP-1998, from NeurogesX Inc (OTC Markets:NGSX).

SCR, LDK, FIG, NGSX, ESSA, DGICA Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Fri Feb 08, 6:59AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Score Media Inc (NYSE:SCR), LDK Solar Co Ltd (NYSE:LDK), Fortress Investment Group LLC (NYSE:FIG), NeurogesX Inc (NASDAQ:NGSX), ESSA Bancorp Inc (NASDAQ:ESSA), Donegal Group Inc (NASDAQ GICA) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:

OMPI, GLUU, NGSX, MWA, REXX, CVGI Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Tue Jan 08, 6:53AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Obagi Medical Products Inc (NASDAQ:OMPI), Glu Mobile Inc (NASDAQ:GLUU), NeurogesX Inc (NASDAQ:NGSX), Mueller Water Products Inc (NYSE:MWA), Rex Energy Corp (NASDAQ:REXX), Commercial Vehicle Group Inc (NASDAQ:CVGI) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
Scroll down for more posts ▼

Top 10 Most Recent News Articles

D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 98

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Debevoise Builds Its PE M&A Bench With McBain Hire

Updated Category News Views 92

Law-firm hiring rarely makes a market blink, yet this one carries a decent whiff of where the deal work is gathering. Debevoise & Plimpton has brought Jenna McBain into its New York Mergers & Acquisitions Group as a partner, putting another experienced private-equity adviser on a platform the firm plainly intends to keep enlarging. McBain arrives from Weil, Gotshal &...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 110

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
CASEKOO's Montana Story Makes Brand Purpose Personal

Updated Category News Views 50

A blurry Montana kitchen, not a glossy product render, is doing the heavy lifting for CASEKOO this Thanksgiving. That is either a smart bit of brand discipline or a sentimental detour, depending on whether the company can make people feel something without losing sight of why they bought a phone case in the first place. Warmth Takes the Place of Hardware CASEKOO's new...

Continue Reading
Chord's $550 Million Exit Tightens Its Basin Focus

Updated Category News Views 69

One map pin just disappeared from Chord Energy’s corporate wall, and that matters more than the usual deal-closing confetti. Chord has completed the sale of its entire non-operated Marcellus position to POSCO International for $550 million in gross consideration. For shareholders in NASDAQ:CHRD, this is not a flashy new drilling story. It is a cleanup job, and sometimes...

Continue Reading
Tampa General's Food Bet Earns a 2026 Innovation Award

Updated Category News Views 78

Hospital meals have long been the punchline nobody bothered to fix, which is why Tampa General Hospital's latest recognition deserves a closer look. The not-for-profit academic health system was named the 2026 Inno Pick by the Tampa Bay Business Journal for its Food as Medicine initiative, its fifth straight year landing among the publication's Inno Award honorees. Awards...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 169

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
Pinnacol’s Community Work Earns Denver Chamber Recognition

Updated Category News Views 67

A workers’ comp insurer usually becomes visible on somebody’s worst day; Pinnacol Assurance is being recognized for the work it keeps doing around those days. The Denver Metro Chamber of Commerce has given the Colorado-based, member-owned carrier its 2026 Business Impact Award for Corporate Social Responsibility. Awards can be cheap applause, frankly. This one...

Continue Reading
SEIA's Young Advisors Put Succession Plans to the Test

Updated Category News Views 67

A $166 million average book is not a cute training-program statistic. It says SEIA’s advisors aged 30 to 39 are already carrying serious client responsibility, and that matters because the registered investment advisory business is headed into a succession crunch nobody can solve with a glossy recruiting brochure. You Cannot Hand Off Trust Like a Spare Key Clients may...

Continue Reading
Webster First Takes Aim at the Youth Money Literacy Gap

Updated Category News Views 86

Money mistakes get expensive long before anyone calls them mistakes. That is the uncomfortable point beneath Webster First Federal Credit Union CEO John Thomasian's November 20, 2026 discussion of financial literacy: plenty of young adults are entering the real financial world with a card, a loan offer, and a phone full of banking apps, but no sturdy framework for using...

Continue Reading

Top 5 Most Recently Viewed Articles

Ross Gerber Expresses Optimism for Meta's Phone-Free Future

Updated Category News Views 242

Ross Gerber Praises Meta's Smart Glasses Technology Over the weekend, investor Ross Gerber expressed his admiration for Meta Platforms, Inc. (NASDAQ: META) smart glasses, affirming their potential to transform our relationship with technology. Gerber noted that this innovative eyewear gives him hope for a day when he might no longer rely on his smartphone. Smart Glasses:...

Continue Reading
Organ-on-a-Chip Market Insights and Future Projections

Updated Category News Views 118

Understanding the Organ-on-a-Chip Market Growth As technology evolves, the quest for more accurate and human-relevant drug testing models takes center stage. The Organ-on-a-Chip (OOC) market has emerged as a revolutionary force, previously valued at around USD 117.67 million, and now set to skyrocket to approximately USD 1.64 billion by 2032. This innovative approach is...

Continue Reading
Discovering Blue Light Cystoscopy Benefits in Bladder Cancer

Updated Category News Views 240

New Insights on Blue Light Cystoscopy and Bladder Cancer Photocure ASA, known as the Bladder Cancer Company, has made significant advancements in bladder cancer management with the recent study titled "Oncologic Outcomes of Blue Light Cystoscopy in an Equal Access Setting: Results of the BRAVO Study." This research published in JU Open Plus provides compelling evidence...

Continue Reading
BioCryst's Bold Move: Astria Therapeutics Acquisition Insights

Updated Category News Views 211

BioCryst Enhances HAE Portfolio with Astria Acquisition BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) has made a significant announcement regarding its acquisition of Astria Therapeutics, Inc. (NASDAQ: ATXS). This strategic move will strengthen BioCryst's position in the hereditary angioedema (HAE) market, as they plan to integrate Astria's promising therapies and...

Continue Reading
Milestone Scientific Reaches New Height with Strong Growth

Updated Category News Views 361

Milestone Scientific Achieves 52-Week High Milestone Scientific Inc. (NYSE: MLSS) has reached a significant milestone with its stock trading at $1.28, marking a 52-week high. This impressive achievement highlights the company's robust annual growth and increased investor confidence. As a result, the current market capitalization has reached approximately $97.37 million,...

Continue Reading